AVE Secures US & EU Patent Allowances for CBD Soft-Gel
| Stock | Avecho Biotechnology Ltd (AVE.ASX) |
|---|---|
| Release Time | 3 Dec 2025, 11:32 a.m. |
| Price Sensitive | Yes |
Avecho Secures US & EU Patent Allowances for CBD Soft-Gel
- Patent applications allowed in the US and Europe covering Avecho's proprietary CBD TPM® soft-gel capsule
- Coverage extends to formulations incorporating cannabinoids beyond CBD
- Grant of patents expected by the end of FY26, protecting the CBD TPM® soft-gel capsule until at least 2040
Avecho Biotechnology Limited (ASX: AVE) has announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have allowed the company's patent applications relating to its proprietary cannabidiol (CBD) TPM® soft-gel capsule, designed to enhance the absorption of CBD. The US and European applications, titled 'Oral cannabinoid formulation comprising tocopheryl phosphates and long chain triglycerides or long chain fatty acids', expand Avecho's intellectual property protection around its oral cannabinoid delivery technology in two major global markets. With all substantive examination hurdles now passed, the company expects formal grant of the patents by the end of FY26. Once granted, the patents will protect the novel combination of Tocopheryl Phosphate Mixture (TPM), cannabinoid, and lipid that forms the basis of Avecho's CBD soft-gel capsule until at least 2040. Avecho is currently conducting a pivotal, multi-centre, randomised, double-blind, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its CBD TPM soft-gel capsule for the treatment of insomnia. The study, designed in consultation with international sleep and regulatory experts, is the largest global trial of cannabidiol for insomnia and is expected to support a planned submission to the TGA for registration of the CBD TPM soft-gel capsule for the management of insomnia in Australia.
No high-importance, price-sensitive forward-looking financial metrics or other company-specific metrics provided.
Avecho has an opportunity to be the first to market with an over-the-counter CBD product for insomnia in Australia, where regulatory changes in 2020 allow for such sales direct from pharmacy without a prescription, provided they gain appropriate approvals. Initial projections estimated the Australian over-the-counter CBD market would grow to over US$125M per annum.